|Awarded On||August 16, 2017|
|Title||Identification of Critical Dependencies and Actionable Therapeutic Options in Smarcb1-Deficient Pediatric Tumors|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Giulio Draetta|
|Cancer Sites||Gallbladder, Kidney and Renal Pelvis, Liver and Intrahepatic Bile Duct|
Cells have special enzymes that control how genes are expressed. Because of this, even when two people may share the same genes, these enzymes can impact how those genes are expressed and influence physiological processes. Increasingly, we are understanding that these enzymes controlling gene expression may significantly impact the development and progression of cancer. The function of one of these enzymes, Smarcb1, has been documented to be lost in a group of very aggressive pediatric tumors, malignant rhabdoid tumors (MRTs) and renal medullary carcinomas (RMCs). Although very rare, patients with these tumors suffer an overall dismal prognosis, especially very young patients under one year ...